© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 22, 1823-1830,
November 15, 2000
© 2000 Oxford University Press
Highly Active Antiretroviral Therapy and Incidence of Cancer in Human Immunodeficiency Virus-Infected Adults
Affliations of the analysis and writing group: P. Appleby, V. Beral, R. Newton, G. Reeves, Cancer Epidemiology Unit, Imperial Cancer Research Fund (ICRF), Oxford, U.K.; L. Carpenter, Department of Public Health, Oxford University.
Correspondence to: Professor Valerie Beral, Secretariat International Collaboration on HIV and Cancer, ICRF, Cancer Epidemiology Unit, Gibson Bldg., The Radcliffe Infirmary, Woodstock Rd., Oxford OX2 6HE, U.K. (e-mail: hivcancer{at}icrf.icnet.uk).
Background: The risk of Kaposi's sarcoma and non-Hodgkin's lymphoma is increased in people infected with the human immunodeficiency virus-1 (HIV). Highly active antiretroviral therapy (HAART) has been widely used by HIV-infected people in North America, Europe, and Australia since about 1997. Acquired immunodeficiency syndrome (AIDS) incidence and mortality rates have fallen markedly in association with the use of HAART, but its impact on the incidence of cancer in HIV-infected people is less clear. Methods: Cancer incidence data from 23 prospective studies that included 47 936 HIV-seropositive individuals from North America, Europe, and Australia were collated, checked, and analyzed centrally. Adjusted incidence rates (expressed as number of cancers per 1000 person-years) for Kaposi's sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, cervical cancer, and 20 other cancer types or sites were calculated. Rate ratios were estimated, comparing incidence rates from 1997 through 1999 with rates from 1992 through 1996, after adjustment for study, age, sex, and HIV transmission group. All statistical tests were two-sided. Results: For the period from 1992 through 1999, 2702 incident cancers were reported in 138 148 person-years of observation, and more than 90% of them were either Kaposi's sarcoma or non-Hodgkin's lymphoma. The adjusted incidence rate for Kaposi's sarcoma declined from 15.2 in 1992 through 1996 to 4.9 in 1997 through 1999 (rate ratio = 0.32; 99% confidence interval [CI] = 0.260.40; based on 1489 and 190 cases, respectively; P<.0001). The incidence rates for non-Hodgkin's lymphoma also declined, from 6.2 to 3.6 (rate ratio = 0.58; 99% CI = 0.450.74; based on 623 and 134 cases, respectively; P<.0001). Among the lymphomas, the rate ratios were 0.42 (99% CI = 0.240.75) for cerebral lymphoma, 0.57 (99% CI = 0.390.85) for immunoblastic lymphoma, and 1.18 (99% CI = 0.482.88) for Burkitt's lymphoma (
22 for heterogeneity = 6.2; P = .05). There was no statistically significant change in the incidence rates for Hodgkin's disease (rate ratio = 0.77; 99% CI = 0.321.85; based on 38 and 12 cases, respectively; P = .4) or for cervical cancer (rate ratio = 1.87; 99% CI = 0.774.56; based on 19 and 17 cases, respectively; P = .07). The adjusted incidence rate for all other cancers combined was 1.7 in each time period (rate ratio = 0.96; 99% CI = 0.621.47; based on 126 and 54 cases, respectively). Conclusions: Since the widespread use of HAART, there have been substantial reductions in the incidence Kaposi's sarcoma and non-Hodgkin's lymphoma in HIV-infected people but, so far, no substantial change in the incidence of other cancers.
This article has been cited by other articles:
![]() |
A. K. Chaturvedi, M. M. Madeleine, R. J. Biggar, and E. A. Engels Risk of Human Papillomavirus-Associated Cancers Among Persons With AIDS J Natl Cancer Inst, August 19, 2009; 101(16): 1120 - 1130. [Abstract] [Full Text] [PDF] |
||||
![]() |
E J Bini, B Green, and M A Poles Screening colonoscopy for the detection of neoplastic lesions in asymptomatic HIV-infected subjects Gut, August 1, 2009; 58(8): 1129 - 1134. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Crum-Cianflone, K. H. Hullsiek, E. Satter, V. Marconi, A. Weintrob, A. Ganesan, R. V. Barthel, S. Fraser, and B. K. Agan Cutaneous Malignancies Among HIV-Infected Persons Arch Intern Med, June 22, 2009; 169(12): 1130 - 1138. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bower, M. Fisher, T. Hill, I. Reeves, J. Walsh, C. Orkin, A. N. Phillips, L. Bansi, R. Gilson, P. Easterbrook, et al. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK Haematologica, June 1, 2009; 94(6): 875 - 880. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Powles, D. Robinson, J. Stebbing, J. Shamash, M. Nelson, B. Gazzard, S. Mandelia, H. Moller, and M. Bower Highly Active Antiretroviral Therapy and the Incidence of Non-AIDS-Defining Cancers in People With HIV Infection J. Clin. Oncol., February 20, 2009; 27(6): 884 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Patel, D. L. Hanson, P. S. Sullivan, R. M. Novak, A. C. Moorman, T. C. Tong, S. D. Holmberg, J. T. Brooks, and for the Adult and Adolescent Spectrum of Disease P Incidence of Types of Cancer among HIV-Infected Persons Compared with the General Population in the United States, 1992-2003 Ann Intern Med, May 20, 2008; 148(10): 728 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
K L Grogg, R F Miller, and A Dogan HIV infection and lymphoma J. Clin. Pathol., December 1, 2007; 60(12): 1365 - 1372. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Galicier, C. Fieschi, R. Borie, V. Meignin, M.-T. Daniel, L. Gerard, and E. Oksenhendler Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study Blood, October 15, 2007; 110(8): 2846 - 2854. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. B. Godoy, H. Rouse, J. A. Brown, P. Phillips, D. M. Forrest, and N. L. Muller Imaging Features of Pulmonary Kaposi Sarcoma Associated Immune Reconstitution Syndrome Am. J. Roentgenol., October 1, 2007; 189(4): 956 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Biggar, A. K. Chaturvedi, J. J. Goedert, and E. A. Engels AIDS-Related Cancer and Severity of Immunosuppression in Persons With AIDS J Natl Cancer Inst, June 20, 2007; 99(12): 962 - 972. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stebbing, A. Sanitt, A. Teague, T. Powles, M. Nelson, B. Gazzard, and M. Bower Prognostic Significance of Immune Subset Measurement in Individuals With AIDS-Associated Kaposi's Sarcoma J. Clin. Oncol., June 1, 2007; 25(16): 2230 - 2235. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Chiappini, L. Galli, P.-A. Tovo, C. Gabiano, C. Lisi, C. Giaquinto, O. Rampon, G. C. Gattinara, G. De Marco, P. Osimani, et al. Cancer Rates After Year 2000 Significantly Decrease in Children With Perinatal HIV Infection: A Study by the Italian Register for HIV Infection in Children J. Clin. Oncol., January 1, 2007; 25(1): 97 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Cooley, D. Henry, M. Tonda, S. Sun, M. O'Connell, and W. Rackoff A Randomized, Double-Blind Study of Pegylated Liposomal Doxorubicin for the Treatment of AIDS-Related Kaposi's Sarcoma Oncologist, January 1, 2007; 12(1): 114 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Joshi, N. Markelova, D. Palacio, and R. M. Schapira A Patient With HIV, Dyspnea, and Multiple Pulmonary Nodules Chest, December 1, 2006; 130(6): 1924 - 1928. [Full Text] [PDF] |
||||
![]() |
C. Palmieri, T. Treibel, O. Large, and M. Bower AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy QJM, December 1, 2006; 99(12): 811 - 826. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Biggar, E. S. Jaffe, J. J. Goedert, A. Chaturvedi, R. Pfeiffer, E. A. Engels, and for the HIV/AIDS Cancer Match Study Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS Blood, December 1, 2006; 108(12): 3786 - 3791. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Cadranel, D Garfield, A Lavole, M Wislez, B Milleron, and C Mayaud Lung cancer in HIV infected patients: facts, questions and challenges. Thorax, November 1, 2006; 61(11): 1000 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Bini, J. Park, and F. Francois Use of Flexible Sigmoidoscopy to Screen for Colorectal Cancer in HIV-Infected Patients 50 Years of Age and Older. Arch Intern Med, August 14, 2006; 166(15): 1626 - 1631. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bower, T. Powles, M. Nelson, S. Mandalia, B. Gazzard, and J. Stebbing Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst, August 2, 2006; 98(15): 1088 - 1091. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Grabar, B. Abraham, A. Mahamat, P. Del Giudice, E. Rosenthal, and D. Costagliola Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement J. Clin. Oncol., July 20, 2006; 24(21): 3408 - 3414. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sandin, H. Hjalgrim, B. Glimelius, K. Rostgaard, E. Pukkala, and J. Askling Incidence of Non-Hodgkin's Lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an Epidemic That Was. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1295 - 1300. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bower, D. Mazhar, and J. Stebbing Should Cervical Cancer Be an Acquired Immunodeficiency Syndrome-Defining Cancer? J. Clin. Oncol., June 1, 2006; 24(16): 2417 - 2419. [Full Text] [PDF] |
||||
![]() |
M. Hentrich, L. Maretta, K. U. Chow, J. R. Bogner, D. Schurmann, P. Neuhoff, H. Jager, D. Reichelt, M. Vogel, M. Ruhnke, et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study Ann. Onc., June 1, 2006; 17(6): 914 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Combs, N. Neil, and D. M. Aboulafia Liposomal Doxorubicin, Cyclophosphamide, and Etoposide and Antiretroviral Therapy for Patients with AIDS-Related Lymphoma: A Pilot Study. Oncologist, June 1, 2006; 11(6): 666 - 673. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stebbing, D. Mazhar, R. Lewis, C. Palmieri, E. Hatzimichael, M. Nelson, B. Gazzard, and M. Bower The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma Ann. Onc., March 1, 2006; 17(3): 503 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Morton, S. S. Wang, S. S. Devesa, P. Hartge, D. D. Weisenburger, and M. S. Linet Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 Blood, January 1, 2006; 107(1): 265 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Kaplan, J. Y. Lee, R. F. Ambinder, J. A. Sparano, E. Cesarman, A. Chadburn, A. M. Levine, and D. T. Scadden Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 Blood, September 1, 2005; 106(5): 1538 - 1543. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hoffmann, M. Tiemann, C. Schrader, D. Janssen, E. Wolf, M. Vierbuchen, R. Parwaresch, K. Ernestus, A. Plettenberg, A. Stoehr, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping Blood, September 1, 2005; 106(5): 1762 - 1769. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bower, B. Gazzard, S. Mandalia, T. Newsom-Davis, C. Thirlwell, T. Dhillon, A. M. Young, T. Powles, A. Gaya, M. Nelson, et al. A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy Ann Intern Med, August 16, 2005; 143(4): 265 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Lim and A. M. Levine Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)-related Lymphoma CA Cancer J Clin, July 1, 2005; 55(4): 229 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Lim, R. Karim, B. N. Nathwani, A. Tulpule, B. Espina, and A. M. Levine AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre-Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemotherapy J. Clin. Oncol., July 1, 2005; 23(19): 4430 - 4438. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Cheung, L. Pantanowitz, and B. J. Dezube AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy Oncologist, June 1, 2005; 10(6): 412 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Engels and J. J. Goedert Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome and Cancer: Past, Present, and Future J Natl Cancer Inst, March 16, 2005; 97(6): 407 - 409. [Full Text] [PDF] |
||||
![]() |
G. M. Clifford, J. Polesel, M. Rickenbach, on behalf of the Swiss HIV Cohort Study, L. Dal Maso, O. Keiser, A. Kofler, E. Rapiti, F. Levi, G. Jundt, et al. Cancer Risk in the Swiss HIV Cohort Study: Associations With Immunodeficiency, Smoking, and Highly Active Antiretroviral Therapy J Natl Cancer Inst, March 16, 2005; 97(6): 425 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global Cancer Statistics, 2002 CA Cancer J Clin, March 1, 2005; 55(2): 74 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Gallafent, S. E. Buskin, P. B. De Turk, and D. M. Aboulafia Profile of Patients With Kaposi's Sarcoma in the Era of Highly Active Antiretroviral Therapy J. Clin. Oncol., February 20, 2005; 23(6): 1253 - 1260. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Noy, D. T. Scadden, J. Lee, B. J. Dezube, D. Aboulafia, A. Tulpule, S. Walmsley, and P. Gill Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team J. Clin. Oncol., February 10, 2005; 23(5): 990 - 998. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Krishnan, A. Molina, J. Zaia, D. Smith, D. Vasquez, N. Kogut, P. M. Falk, J. Rosenthal, J. Alvarnas, and S. J. Forman Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas Blood, January 15, 2005; 105(2): 874 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bower, N. McCall-Peat, N. Ryan, L. Davies, A. M. Young, S. Gupta, M. Nelson, B. Gazzard, and J. Stebbing Protease inhibitors potentiate chemotherapy-induced neutropenia Blood, November 1, 2004; 104(9): 2943 - 2946. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Rivailler, A. Carville, A. Kaur, P. Rao, C. Quink, J. L. Kutok, S. Westmoreland, S. Klumpp, M. Simon, J. C. Aster, et al. Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: an animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host Blood, September 1, 2004; 104(5): 1482 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ahdieh-Grant, R. Li, A. M. Levine, L. S. Massad, H. D. Strickler, H. Minkoff, M. Moxley, J. Palefsky, H. Sacks, R. D. Burk, et al. Highly Active Antiretroviral Therapy and Cervical Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women J Natl Cancer Inst, July 21, 2004; 96(14): 1070 - 1076. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stebbing, B. Gazzard, S. Mandalia, A. Teague, A. Waterston, V. Marvin, M. Nelson, and M. Bower Antiretroviral Treatment Regimens and Immune Parameters in the Prevention of Systemic AIDS-Related Non-Hodgkin's Lymphoma J. Clin. Oncol., June 1, 2004; 22(11): 2177 - 2183. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Sparano, S. Lee, M. G. Chen, T. Nazeer, A. Einzig, R. F. Ambinder, D. H. Henry, J. Manalo, T. Li, and J. H. Von Roenn Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494) J. Clin. Oncol., April 15, 2004; 22(8): 1491 - 1500. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Krown Highly Active Antiretroviral Therapy in AIDS-Associated Kaposi's Sarcoma: Implications for the Design of Therapeutic Trials in Patients With Advanced, Symptomatic Kaposi's Sarcoma J. Clin. Oncol., February 1, 2004; 22(3): 399 - 402. [Full Text] [PDF] |
||||
![]() |
J. Stebbing, A. Wildfire, S. Portsmouth, T. Powles, C. Thirlwell, P. Hewitt, M. Nelson, S. Patterson, S. Mandalia, F. Gotch, et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations Ann. Onc., November 1, 2003; 14(11): 1660 - 1666. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Kaplan, N. A. Afridi, G. Holmvang, and L. R. Zukerberg Case 31-2003 - A 44-Year-Old Man with HIV Infection and a Right Atrial Mass N. Engl. J. Med., October 2, 2003; 349(14): 1369 - 1377. [Full Text] [PDF] |
||||
![]() |
M. Herida, M. Mary-Krause, R. Kaphan, J. Cadranel, I. Poizot-Martin, C. Rabaud, N. Plaisance, H. Tissot-Dupont, F. Boue, J.-M. Lang, et al. Incidence of Non-AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus-Infected Patients J. Clin. Oncol., September 15, 2003; 21(18): 3447 - 3453. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stebbing, B. Gazzard, S. Portsmouth, F. Gotch, L. Kim, M. Bower, S. Mandalia, R. Binder, P. Srivastava, and S. Patterson Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor Blood, September 1, 2003; 102(5): 1806 - 1814. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stebbing, S. Portsmouth, and B. Gazzard How does HAART lead to the resolution of Kaposi's sarcoma? J. Antimicrob. Chemother., May 1, 2003; 51(5): 1095 - 1098. [Full Text] [PDF] |
||||
![]() |
P. Monini, C. Sgadari, G. Barillari, and B. Ensoli HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity J. Antimicrob. Chemother., February 1, 2003; 51(2): 207 - 211. [Full Text] [PDF] |
||||
![]() |
M. A. Eltom, A. Jemal, S. M. Mbulaiteye, S. S. Devesa, and R. J. Biggar Trends in Kaposi's Sarcoma and Non-Hodgkin's Lymphoma Incidence in the United States From 1973 Through 1998 J Natl Cancer Inst, August 21, 2002; 94(16): 1204 - 1210. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Otieno, C. Banura, E. Katongole-Mbidde, J. L. Johnson, M. Ghannoum, A. Dowlati, R. Renne, E. Arts, C. Whalen, M. M. Lederman, et al. Therapeutic Challenges of AIDS-Related Non-Hodgkin's Lymphoma in the United States and East Africa J Natl Cancer Inst, May 15, 2002; 94(10): 718 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wilkinson, A. Cope, J. Gill, D. Bourboulia, P. Hayes, N. Imami, T. Kubo, A. Marcelin, V. Calvez, R. Weiss, et al. Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy J. Virol., February 22, 2002; 76(6): 2634 - 2640. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, M. Law, A. McDonald, P. Correll, J. M. Kaldor, and A. E. Grulich Estimation of Risk of Cancers before Occurrence of Acquired Immunodeficiency Syndrome in Persons Infected with Human Immunodeficiency Virus Am. J. Epidemiol., January 15, 2002; 155(2): 153 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Kirk, C. Pedersen, A. Cozzi-Lepri, F. Antunes, V. Miller, J. M. Gatell, C. Katlama, A. Lazzarin, P. Skinhoj, and S. E. Barton Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy Blood, December 1, 2001; 98(12): 3406 - 3412. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Besson, A. Goubar, J. Gabarre, W. Rozenbaum, G. Pialoux, F.-P. Chatelet, C. Katlama, F. Charlotte, B. Dupont, N. Brousse, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy Blood, October 15, 2001; 98(8): 2339 - 2344. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Martin and M. Bower Anal intraepithelial neoplasia in HIV positive people Sex Transm Inf, October 1, 2001; 77(5): 327 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Frisch, R. J. Biggar, E. A. Engels, J. J. Goedert, and for the AIDS-Cancer Match Registry Study Group Association of Cancer With AIDS-Related Immunosuppression in Adults JAMA, April 4, 2001; 285(13): 1736 - 1745. [Abstract] [Full Text] [PDF] |
||||





















